Skip to main content

Table 1 Baseline Patient Demographics and Clinical Characteristics of Patients With and Without Allodynia

From: Effects of onabotulinumtoxinA treatment in patients with and without allodynia: results of the COMPEL study

  With Allodynia
(n = 289)
Without Allodynia
(n = 426)
Mean (SD) age, y 42.3 (11.3) 43.5 (11.2)
 Min, max 18,72 18,73
Female, n (%) 251 (86.9) 355 (83.3)
Race, n (%)
 Caucasian 240 (83.0) 341 (80.0)
 Black 16 (5.5) 25 (5.9)
 Asian 31 (10.7) 58 (13.6)
 Native Hawaiian or other Pacific Islander 1 (0.3) 2 (0.5)
 American Indian or Alaska Native 1 (0.3) 0 (0.0)
 Mean (SD) BMI, kg/m2 27.6 (6.5) 27.3 (6.4)
 Mean (SD) age of migraine onset, y 32.2 (13.1) 32.7 (14.1)
 Mean (SD) time since onset of migraine, y 10.2 (10.5) 10.8 (11.3)
 Family history of migraine, n (%) 179 (61.7) 270 (63.4)
 Mean (SD) headache days at baseline 21.7 (4.8) 21.9 (4.9)
 Mean (SD) moderate to severe headache days at baseline 17.9 (5.6) 17.8 (5.7)
Medication use at baseline, n (%)*
 Previously taken acute medications 288 (99.3) 419 (98.4)
 Previously taken preventive medications 244 (84.1) 335 (78.6)
  1. BMI body mass index
  2. *Data were based on the safety population
\